Skip to main content
Donate

Indexing and Metadata

FAST-DART is committed to maintaining high standards of scholarly publishing through accurate metadata, persistent identifiers, and transparent indexing practices. Proper indexing and metadata management ensure that published articles are discoverable, citable, and permanently accessible to the scientific community.

DOI Policy

All articles published in FAST-DART are assigned a Digital Object Identifier (DOI) to provide a permanent and reliable link to the scholarly record.

Crossref Registration

FAST-DART registers DOIs through Crossref, a leading registration agency for scholarly publications. Each article receives a unique DOI upon publication, which is permanently associated with the article’s metadata and landing page.

Metadata Completeness

The journal maintains comprehensive metadata for each article to support accurate indexing, citation tracking, and long term discoverability. Metadata deposited with Crossref includes, where applicable, article title, author names and affiliations, abstract, keywords, publication date, licensing information, references, and funding acknowledgments. FAST-DART strives to maintain complete and accurate metadata records to ensure compatibility with indexing services and bibliographic databases.

Indexing Goals

FAST-DART aims to ensure broad discoverability of published research through inclusion in recognized scientific indexing services and bibliographic databases.

PubMed Central Application

FAST-DART intends to pursue inclusion in PubMed Central (PMC) once eligibility criteria are met. The journal is structured to comply with the scientific, editorial, and technical standards required for PMC participation, including transparent peer review processes, consistent article formatting, and high-quality metadata.

Database Indexing Transparency

The journal maintains transparency regarding indexing status. Current and future indexing services will be clearly listed on the FAST-DART website. The journal does not claim inclusion in any database until formal acceptance has been confirmed.

Privacy and Data Use

FAST-DART respects the privacy of authors, reviewers, and readers and is committed to responsible handling of personal information collected through the journal website.

Cookies

The website may use cookies to improve functionality, monitor website performance, and enhance user experience. Cookies do not collect personally identifiable information beyond what is necessary for site operation and analytics.

Email List Use

Email addresses collected for manuscript submission, journal updates, or newsletter distribution will be used solely for communication related to FAST-DART activities. Email information will not be sold, shared, or distributed to third parties for marketing purposes.

GDPR Statement

Where applicable, FAST-DART complies with the principles of the General Data Protection Regulation (GDPR) and other relevant privacy regulations. Users may request access to, correction of, or deletion of personal information held by the journal, subject to applicable legal and editorial requirements.

FAST Angelman Syndrome News

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.